Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
PR Newswire (AI)en
PR Newswire (AI)
AI Global WireLunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a research agreement to evaluate the use of Lunit ...
This is a short summary published by AI Global Wire. The full article is owned and hosted by PR Newswire (AI) — open it there to read it in full.
Read the full story at PR Newswire (AI)- Verktyg
- Forskning
Related AI news
- China’s AI compute surge heavily reliant on US chips, offshore cloud access: reportSCMP Tech · October 24, 2026
- Moonshot AI launches new flagship Kim K3.1 Pro model with 3T parametersSiliconANGLE · October 24, 2026
- OpenAI says it built an "offline world" from cached web content to train isolated frontier models to browse, search for information, and use web apps (OpenAI)Techmeme · October 24, 2026
- Anthropic reveals Mythos 5 tried submitting malicious code to an open-source projectSiliconANGLE · October 23, 2026
- Kyutai CADRE: Video Autoencoders That Cut World Model Lag Below 230 msMarkTechPost · October 23, 2026
- Three insights you may have missed from theCUBE’s coverage of Oracle’s “AI Cyberattacks Are Escalating: How to Secure Your Data Now” virtual eventSiliconANGLE · October 23, 2026